0000939767-17-000025.txt : 20170303 0000939767-17-000025.hdr.sgml : 20170303 20170303202012 ACCESSION NUMBER: 0000939767-17-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170303 FILED AS OF DATE: 20170303 DATE AS OF CHANGE: 20170303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Senner Christopher J. CENTRAL INDEX KEY: 0001648367 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 17666248 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wf-form4_148859039767320.xml FORM 4 X0306 4 2017-03-03 0 0000939767 EXELIXIS, INC. EXEL 0001648367 Senner Christopher J. C/O EXELIXIS, INC. 210 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP and CFO Common Stock 2017-03-03 4 S 0 11000 22.80 D 100398 D Common Stock 1783 I By 401(k) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.80 to $22.81. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 5,422 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. The total number of shares reported has been reduced by 20,000 shares due to prior inadvertent over-reporting of the total number of shares beneficially owned by the Reporting Person. Represents 1,783 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 2, 2017. /s/ Jeffrey J. Hessekiel, Attorney in Fact 2017-03-03